Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. The company's products portfolio includes valsartan, losartan, clopidogrel, perindopril, rosuvastatin ca, atorvastatin ca, pregabalin, and other products. It offers APIs, intermediates, and preparations for the treatment of cardiovascular, central nervous, gastrointestinal and digestive tracts, and other therapeutic areas. The company was founded in 2004 and is headquartered in Ningbo, China.
Research context
Ningbo Menovo Pharmaceutical Co., Ltd appears in PyInvesting’s Shanghai Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Ningbo Menovo Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 19.9% above its 200 day moving average.
From a valuation standpoint, the stock is 59.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.9.
Ningbo Menovo Pharmaceutical Co., Ltd's total revenue rose by 2.4% to $297M since the same quarter in the previous year.
Its net income has dropped by 19.5% to $34M since the same quarter in the previous year.
Finally, its free cash flow grew by 130.4% to $29M since the same quarter in the previous year.
Based on the above factors, Ningbo Menovo Pharmaceutical Co., Ltd gets an overall score of 4/5.